A combination of two drugs used to treat a form of kidney cancer has shown promise in a clinical trial involving patients with a hard-to-treat type of endometrial cancer, researchers at Dana-Farber Cancer Institute will report at the 2024 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer in San Diego today.
The drugs, avelumab and axitinib, exploit different vulnerabilities of endometrial cancer cells. Avelumab is an immune checkpoint inhibitor that exposes tumor cells to an immune system attack; axitinib blocks the growth of blood vessels in tumors and stymies the growth of tumor cells. Together, they’re approved as a first-line treatment for patients with advanced renal cell cancer.
